Key findings Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr
Like liraglutide, semaglutide incorporates an Aib substitution at the 8th position in place of Ala, which confers resistance to enzymatic degradation by DPP-4
Is retatrutide legal in Australia
Factors such as nutrition, overall health, and how quickly the underlying trigger is addressed all play a role
GLP-1 analogues cross the bloodbrain barrier and may enhance synaptic plasticity, raising the question of synergy in preventing cognitive decline